GAMMA Investing LLC Takes Position in IQVIA Holdings Inc. (NYSE:IQV)

GAMMA Investing LLC bought a new position in IQVIA Holdings Inc. (NYSE:IQV) during the 4th quarter, Holdings Channel reports. The institutional investor bought 261 shares of the medical research company’s stock, valued at approximately $60,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. AdvisorNet Financial Inc grew its stake in IQVIA by 327.6% during the fourth quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock worth $29,000 after buying an additional 95 shares during the period. BKM Wealth Management LLC purchased a new stake in IQVIA during the 4th quarter worth $32,000. Activest Wealth Management acquired a new stake in IQVIA in the 4th quarter valued at $35,000. CVA Family Office LLC purchased a new position in IQVIA in the fourth quarter valued at about $43,000. Finally, CoreFirst Bank & Trust acquired a new position in shares of IQVIA during the third quarter worth about $44,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insider Activity

In related news, insider Ari Bousbib sold 31,678 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the sale, the insider now owns 796,752 shares of the company’s stock, valued at approximately $199,610,278.56. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other IQVIA news, insider Eric Sherbet sold 1,000 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $241.50, for a total transaction of $241,500.00. Following the completion of the transaction, the insider now directly owns 20,836 shares of the company’s stock, valued at approximately $5,031,894. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ari Bousbib sold 31,678 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the sale, the insider now owns 796,752 shares in the company, valued at approximately $199,610,278.56. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 41,285 shares of company stock valued at $10,331,003. 1.60% of the stock is currently owned by insiders.

IQVIA Price Performance

Shares of NYSE IQV opened at $232.89 on Thursday. The business has a 50 day simple moving average of $245.07 and a 200-day simple moving average of $223.85. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73. The company has a market capitalization of $42.27 billion, a price-to-earnings ratio of 31.95, a price-to-earnings-growth ratio of 2.28 and a beta of 1.50. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.82 by $0.02. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The company had revenue of $3.87 billion for the quarter, compared to the consensus estimate of $3.80 billion. During the same period last year, the firm posted $2.54 EPS. The company’s revenue for the quarter was up 3.5% on a year-over-year basis. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 10.12 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on IQV shares. Robert W. Baird raised their target price on IQVIA from $226.00 to $251.00 and gave the company a “neutral” rating in a report on Thursday, February 15th. UBS Group boosted their target price on shares of IQVIA from $240.00 to $300.00 and gave the stock a “buy” rating in a research report on Thursday, February 15th. Evercore ISI raised their price target on shares of IQVIA from $255.00 to $265.00 and gave the company a “market outperform” rating in a report on Thursday, February 15th. Leerink Partnrs reiterated an “outperform” rating on shares of IQVIA in a report on Monday, February 26th. Finally, BTIG Research initiated coverage on IQVIA in a research note on Tuesday, February 13th. They set a “buy” rating and a $285.00 target price for the company. Three investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $259.43.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.